Virginia Retirement Systems ET AL Buys Shares of 265,228 Amgen Inc. (AMGN)
Virginia Retirement Systems ET AL bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 265,228 shares of the medical research company’s stock, valued at approximately $40,354,000. Amgen comprises 0.6% of Virginia Retirement Systems ET AL’s investment portfolio, making the stock its 29th largest position.
Several other hedge funds and other institutional investors have also modified their holdings of the stock. Oakworth Capital Inc. raised its position in shares of Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock valued at $111,000 after buying an additional 100 shares during the period. Glassman Wealth Services increased its stake in shares of Amgen by 480.0% in the second quarter. Glassman Wealth Services now owns 725 shares of the medical research company’s stock worth $110,000 after buying an additional 600 shares in the last quarter. Integrated Wealth Management increased its stake in shares of Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock worth $141,000 after buying an additional 3 shares in the last quarter. Delta Asset Management LLC TN increased its stake in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares in the last quarter. Finally, Capital Advisors Ltd. LLC increased its stake in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.
Amgen Inc. (NASDAQ:AMGN) opened at 166.81 on Friday. The company has a 50-day moving average price of $171.68 and a 200-day moving average price of $161.02. Amgen Inc. has a 1-year low of $138.06 and a 1-year high of $176.85. The firm has a market cap of $124.83 billion, a P/E ratio of 17.07 and a beta of 0.87.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The company had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.58 billion. During the same period in the previous year, the company posted $2.57 earnings per share. The firm’s revenue was up 5.9% on a year-over-year basis. On average, equities research analysts forecast that Amgen Inc. will post $11.36 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Wednesday, August 17th were paid a dividend of $1.00 per share. This represents a $4.00 dividend on an annualized basis and a yield of 2.40%. The ex-dividend date of this dividend was Monday, August 15th. Amgen’s payout ratio is 40.90%.
A number of analysts recently weighed in on the stock. Leerink Swann reiterated a “hold” rating on shares of Amgen in a research report on Saturday, September 17th. Vetr upgraded shares of Amgen from a “sell” rating to a “hold” rating and set a $171.34 price target on the stock in a research report on Wednesday, August 3rd. Credit Suisse Group AG set a $206.00 price target on shares of Amgen and gave the company a “buy” rating in a research report on Saturday, September 17th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Amgen in a research report on Wednesday. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $157.00 price target on shares of Amgen in a research report on Friday, August 26th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Amgen currently has an average rating of “Buy” and a consensus target price of $185.06.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of Amgen stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $174.59, for a total transaction of $523,770.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.